A novel WINDOW of opportunity for young mantle cell lymphoma patients
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
The future of cancer therapy innovation
Best treatment strategy for FLT3 ITD AML
Infrastructure for AML treatment in Spain